Apium Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 15-07-2024
- Paid Up Capital ₹ 1.50 M
as on 15-07-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 17.91%
(FY 2020)
- Profit -94.53%
(FY 2020)
- Ebitda 136.70%
(FY 2020)
- Net Worth -71.96%
(FY 2020)
- Total Assets -1.08%
(FY 2020)
About Apium Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rekha Musale and Subhash Musale serve as directors at the Company.
- CIN/LLPIN
U24239MH2009PTC192026
- Company No.
192026
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Washim, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Apium Pharmaceutical Private Limited offer?
Apium Pharmaceutical Private Limited offers a wide range of products and services, including Antibiotic Injection, Piperacillin Tazobactam Injection, Antibiotic Tablets & Capsules, Azithromycin Tablets, Ceftriaxone Injection, Cough Syrup, Anti Inflammatory Drugs, Nimesulide Tablet, Anti Infective Drugs & Medicines, Antibacterial Drugs.
Who are the key members and board of directors at Apium Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rekha Musale  | Director | 01-Dec-2012 | Current |
| Subhash Musale | Director | 24-Apr-2009 | Current |
Financial Performance of Apium Pharmaceutical.
Apium Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 17.91% increase. The company also saw a substantial fall in profitability, with a 94.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 71.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apium Pharmaceutical?
In 2017, Apium Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Apium Pharmaceutical?
Unlock and access historical data on people associated with Apium Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apium Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apium Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
